-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Analysts
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Analysts
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) has received an average rating of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $32.90.
Several analysts recently issued reports on NRIX shares. Morgan Stanley started coverage on Nurix Therapeutics in a research note on Tuesday, October 11th. They issued an "equal weight" rating and a $11.00 price target for the company. SVB Leerink reduced their price target on Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating for the company in a research note on Tuesday, December 13th. Finally, HC Wainwright reduced their price target on Nurix Therapeutics to $53.00 in a research note on Thursday, October 13th.
Get Nurix Therapeutics alerts:Institutional Trading of Nurix Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Swiss National Bank raised its holdings in shares of Nurix Therapeutics by 8.0% during the 1st quarter. Swiss National Bank now owns 47,500 shares of the company's stock worth $665,000 after buying an additional 3,500 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Nurix Therapeutics by 34.1% during the 1st quarter. JPMorgan Chase & Co. now owns 120,516 shares of the company's stock worth $1,688,000 after buying an additional 30,664 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Nurix Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 18,670 shares of the company's stock worth $262,000 after buying an additional 6,891 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Nurix Therapeutics by 4.9% during the 1st quarter. Rhumbline Advisers now owns 33,511 shares of the company's stock worth $469,000 after buying an additional 1,573 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Nurix Therapeutics by 104.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,525 shares of the company's stock worth $3,328,000 after buying an additional 121,167 shares in the last quarter. 91.33% of the stock is currently owned by institutional investors.
Nurix Therapeutics Trading Down 2.9 %
NRIX stock opened at $12.10 on Friday. The firm has a market capitalization of $570.49 million, a PE ratio of -3.26 and a beta of 1.63. Nurix Therapeutics has a 1-year low of $7.52 and a 1-year high of $20.20. The business's 50 day simple moving average is $11.70 and its 200 day simple moving average is $13.60.Nurix Therapeutics Company Profile
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Further Reading
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
据MarketBeat Ratings报道,Nurix治疗公司(纳斯达克代码:NRIX-GET评级)已从目前负责该股的十位分析师那里获得了“中等买入”的平均评级。一位研究分析师对该股的评级为持有建议,六位分析师对该公司发出了买入建议。在去年发布该股报告的经纪商中,12个月目标价的平均水平为32.90美元。
几位分析师最近发布了关于NRIX股票的报告。摩根士丹利在10月11日星期二的一份研究报告中开始了对Nurix治疗公司的报道。他们对该公司进行了“同等权重”评级,并设定了11.00美元的目标价。SVB Leerink在12月13日(星期二)的一份研究报告中将他们对Nurix Treateutics的目标价从37.00美元下调至28.00美元,并为该公司设定了“跑赢大盘”的评级。最后,HC Wainwright在10月13日星期四的一份研究报告中将他们对Nurix治疗公司的目标价下调至53.00美元。
到达纽瑞克斯治疗公司警报:纽瑞克斯治疗公司的制度性交易
一些机构投资者最近调整了对该股的持有量。瑞士国家银行在第一季度增持了Nurix治疗公司的股票8.0%。瑞士国家银行在上个季度又购买了3,500股后,现在持有47,500股该公司股票,价值66.5万美元。摩根大通在第一季度增持了Nurix Treateutics的股票34.1%。摩根大通公司目前持有120,516股该公司股票,价值1,68.8万美元,上一季度又购买了30,664股。大都会人寿投资管理公司在第一季度将其在Nurix Treateutics的股票持有量增加了58.5%。大都会人寿投资管理有限责任公司现在持有18,670股该公司股票,价值26.2万美元,上个季度又购买了6,891股。Rhumbline Advisers在第一季度将其在Nurix Treateutics的股票持有量增加了4.9%。Rhumbline Advisers现在拥有33,511股该公司股票,价值46.9万美元,上个季度又购买了1,573股。最后,Dimension Fund Advisors LP在第一季度将其在Nurix Treateutics的股票持有量增加了104.1%。Dimension Fund Advisors LP现在拥有237,525股该公司股票,价值3,328,000美元,上个季度又购买了121,167股。91.33%的股票目前由机构投资者持有。
Nurix治疗公司股价下跌2.9%
上周五,NRIX股价开盘报12.10美元。该公司市值为5.7049亿美元,市盈率为-3.26,贝塔系数为1.63。Nurix Treateutics的一年低点为7.52美元,一年高位为20.20美元。该业务的50日简单移动均线切入位为11.70美元,200日简单移动均线切入位为13.60美元。纽瑞克斯治疗公司简介
(获取评级)
Nurix治疗公司是一家生物制药公司,专注于治疗癌症和免疫疾病的小分子疗法的发现、开发和商业化。该公司开发了用于治疗复发或难治性B细胞恶性肿瘤的口服布鲁顿酪氨酸激酶(BTK)降解剂NX-2127;用于治疗复发或难治性B细胞恶性肿瘤和自身免疫性疾病的口服生物可用BTK降解剂NX-5948;以及口服可用于免疫肿瘤学适应症的Casitas B细胞性淋巴瘤原癌基因B(CBL-B)抑制剂NX-1607。
进一步阅读
- 免费获取StockNews.com关于Nurix治疗的研究报告(NRIX)
- 雪佛龙以750亿美元的股票回购取悦股东
- 电子商务的未来:分析和新数据
- 列维·施特劳斯非常适合收益型投资者
- 3只小盘股有很大的上涨空间
- 马伦汽车:好消息、坏消息和丑陋的前景
接受《Nurix治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nurix Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧